TELCON RF PHARMACEUTICAL. Inc. Q3 revenue KRW 27.5 billion, loss of KRW 3.0 billion from main business
TAI summary · Not investment advice
Telcon RF Pharmaceutical sold KRW 27.5 billion in Q3 but lost KRW 3.0 billion from its main business; sales rose 180.3% from a year earlier and fell 4.8% from the prior quarter.
Operating profit · 3 months
KRW -3.0 billion
Key facts
- Revenue (3 months)
- KRW 27.5 billion
- Net income (3 months)
- KRW -5.8 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 9.8 billion
- Revenue (year to date)
- KRW 66.2 billion
- Operating profit (prior-year 3 months)
- KRW -8.7 million
- Operating profit (year to date)
- KRW -5.3 billion
- Net income (prior-year 3 months)
- KRW -4.8 billion
- Net income (year to date)
- KRW -39.5 billion
Commentary
AI commentary · Not investment advice
What happened
Telcon RF Pharmaceutical filed its quarterly report for the third quarter of 2026, on a consolidated basis. Sales for the latest 3 months were KRW 27.54 billion. That compares with KRW 9.82 billion in the same 3 months a year earlier. Sales rose 180.3% from a year earlier and fell 4.8% from the previous quarter.
In the company's terms
Operating profit (profit from the main business) for the latest 3 months was a loss of KRW 3.03 billion. A year earlier, the loss was KRW 8.7 million. Net income for the latest 3 months was a loss of KRW 5.77 billion. A year earlier, the loss was KRW 4.85 billion.
What changes for shareholders
For the year to date, from January 1 to September 30, sales were KRW 66.17 billion. Operating profit was a loss of KRW 5.26 billion. Net income was a loss of KRW 39.50 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist